StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

Investment analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, January 21st.

Vanda Pharmaceuticals Stock Up 2.0 %

VNDA stock opened at $4.53 on Tuesday. The company has a market capitalization of $264.14 million, a PE ratio of -16.18 and a beta of 0.77. The stock’s 50 day moving average is $4.72 and its two-hundred day moving average is $4.98. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week high of $6.75.

Insider Buying and Selling at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VNDA. BNP Paribas Financial Markets lifted its holdings in shares of Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the period. FMR LLC increased its holdings in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after buying an additional 30,802 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter worth $864,000. Dimensional Fund Advisors LP raised its position in shares of Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after purchasing an additional 292,172 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Vanda Pharmaceuticals in the 3rd quarter worth about $143,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.